UNCY
NASDAQ · Biotechnology
Unicycive Therapeutics Inc
$8.17
+0.22 (+2.77%)
Open$7.95
Previous Close$7.95
Day High$8.17
Day Low$7.86
52W High$11.00
52W Low$3.71
Volume—
Avg Volume616.4K
Market Cap228.55M
P/E Ratio—
EPS$-2.97
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-23.3% upside
Current
$8.17
$8.17
Target
$6.27
$6.27
$3.63
$6.27 avg
$7.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.90M | 51.72M | 45.87M |
| Net Income | -11,930,457 | -10,903,389 | -10,566,816 |
| Profit Margin | -22.6% | -21.1% | -23.0% |
| EBITDA | -19,602,786 | -19,995,313 | -16,713,067 |
| Free Cash Flow | -9,449,797 | -9,177,412 | -10,735,832 |
| Rev Growth | -5.2% | +18.0% | +24.4% |
| Debt/Equity | 0.52 | 0.63 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |